EUVIMEDEUVIMED entdecken
Crossref

Repurposing eravacycline as an immunomodulator for immunodeficiencies driven by anti-IFN-γ autoantibodies

Yu-Ting Yen, Yi-Hua Pan, Po-Ju Hsiao, Tzu-Tang Wei, Yan-Tung Kiu, Ru-Sing Lee, Yu-Chung Chuang, Jann-Tay Wang, Wang-Huei Sheng, Yee-Chun Chen, Shan-Chwen Chang, Un-In Wu

Translational Research · 2026-06 · 292 · 64-72

DOI: 10.1016/j.trsl.2026.04.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026-06. Verfasst von Yu-Ting Yen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development Center, Institute of Translational Medicine and New Drug Development, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Tetracyclines, Immunomodulating Agents, Immunologic Deficiency Syndromes, Interferon-gamma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Medical University, National Science and Technology Council, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Adult-onset immunodeficiency (AOID) driven by pathogenic anti-interferon-γ (IFN-γ) autoantibodies (AIGA) mimics inborn errors of IFN-γ signaling, causing life-threatening nontuberculous mycobacterial and fungal infections. Current B-cell depletion or prolonged antimicrobials fail to directly reverse autoantibody-mediated IFN-γ blockade. We hypothesized that small molecules binding AIGA-targeted IFN-γ epitopes could sterically disrupt pathogenic autoantibody-cytokine complexes and restore JAK-STAT1 signaling. METHODS: We conducted structure-based high-throughput virtual screening of an FDA-approved drug library using the IFN-γ/IFNGR1 crystal structure (PDB: 1FG9). Compounds predicted to bind AIGA-targeted IFN-γ epitopes were selected for functional testing for their ability to restore IFN-γ signaling inhibited by patient plasma containing AIGA. Patients were stratified into drug-free remission or non-remission groups for comparative analyses. RESULTS: Eravacycline, a tetracycline antibiotic, was identified as a lead candidate with high predicted affinity (-9.1 kcal/mol) for AIGA-targeted IFN-γ epitopes. In functional assays, eravacycline dose-dependently restored IFN-γ-induced STAT1 phosphorylation inhibited by AIGA, outperforming tigecycline under the same conditions (p < 0.001), and partially reversed AIGA-mediated suppression of CXCL9 (p < 0.01) and TNF-α (p < 0.001) expression. These effects were observed in both drug-free remission and non-remission groups. CONCLUSIONS: Eravacycline is the first tetracycline shown to break pathogenic autoantibody-cytokine protein-protein interactions in human disease, restoring Th1 immunity ex vivo. These findings establish proof-of-concept for structure-guided reversal of anti-cytokine autoantibody pathogenicity using an FDA-approved antimicrobial, offering a rapidly translatable dual-action therapy for AIGA-driven AOID and potentially other anti-cytokine autoantibody syndromes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TetracyclinesImmunomodulating AgentsImmunologic Deficiency SyndromesInterferon-gammaDrug RepositioningAutoantibodiesEpitopesSTAT1 Transcription FactorJanus KinasesSignal TransductionPhosphorylationChemokine CXCL9Tumor Necrosis Factor-alphaProspective StudiesMolecular Docking SimulationLongitudinal StudiesFollow-Up StudiesHumansMaleFemaleMiddle AgedAgedTHP-1 CellsProof of Concept Study

Stichwörter der Autor:innen

Adult-Onset Immunodeficiency (AOID)Anti-IFN-γ autoantibodiesDrug repurposingEravacyclineImmunomodulationNTM infections

Substanzen

eravacyclineTetracyclinesImmunomodulating AgentsInterferon-gammaAutoantibodiesEpitopesSTAT1 Transcription FactorJanus KinasesChemokine CXCL9Tumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Drug Development Center, Institute of Translational Medicine and New Drug Development, China Medical University, Taichung, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; National Institute of Infectious Diseases and Vaccinology, National Health Researc…
  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: uninwu@gmail.com.

Förderung

  • China Medical University
  • National Science and Technology Council
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Yen, Y. T., Pan, Y. H., Hsiao, P. J., Wei, T. T., Kiu, Y. T., Lee, R. S., Chuang, Y. C., Wang, J. T., Sheng, W. H., Chen, Y. C., Chang, S. C., & Wu, U. I. (2026). Repurposing eravacycline as an immunomodulator for immunodeficiencies driven by anti-IFN-γ autoantibodies. Translational Research, 292, 64-72. https://doi.org/10.1016/j.trsl.2026.04.006

Vancouver

Yen YT, Pan YH, Hsiao PJ, Wei TT, Kiu YT, Lee RS, et al. Repurposing eravacycline as an immunomodulator for immunodeficiencies driven by anti-IFN-γ autoantibodies. Translational Research. 2026;292:64-72. doi:10.1016/j.trsl.2026.04.006

BibTeX
@article{Yen2026,
  author = {Yen, Yu-Ting and Pan, Yi-Hua and Hsiao, Po-Ju and Wei, Tzu-Tang and Kiu, Yan-Tung and Lee, Ru-Sing and Chuang, Yu-Chung and Wang, Jann-Tay and Sheng, Wang-Huei and Chen, Yee-Chun and Chang, Shan-Chwen and Wu, Un-In},
  title = {Repurposing eravacycline as an immunomodulator for immunodeficiencies driven by anti-IFN-γ autoantibodies},
  journal = {Translational Research},
  year = {2026},
  volume = {292},
  pages = {64--72},
  doi = {10.1016/j.trsl.2026.04.006}
}
Kostenlos starten →